Selección de publicaciones

  • Beekman R, Chapaprieta V, Russiñol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, Duran-Ferrer M, Kulis M, Serra F, Javierre BM, Wingett SW, Clot G, Queirós AC, Castellano G, Blanc J, Gut M, Merkel A, Heath S, Vlasova A, Ullrich S, Palumbo E, Enjuanes A, Martín-García D, Beà S, Pinyol M, Aymerich M, Royo R, Puiggros M, Torrents D, Datta A, Lowy E, Kostadima M, Roller M, Clarke L, Flicek P, Agirre X, Prosper F, Baumann T, Delgado J, López-Guillermo A, Fraser P, Yaspo ML, Guigó R, Siebert R, Martí-Renom MA, Puente XS, López-Otín C, Gut I, Stunnenberg HG, Campo E, Martin-Subero JI. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018 Jun;24(6):868-880.

  • Macias RIR, Sánchez-Martín A, Rodríguez-Macías G, Sánchez-Abarca LI, Lozano E, Herraez E, Odero MD, Díez-Martín JL, Marin JJG, Briz O. Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib. Oncotarget. 2018 Jun 19;9(47):28474-28485.

  • Rabal O, San José-Enériz E, Agirre X, Sánchez-Arias JA, Vilas-Zornoza A, Ugarte A, de Miguel I, Miranda E, Garate L, Fraga M, Santamarina P, Fernandez Perez R, Ordoñez R, Sáez E, Roa S, García-Barchino MJ, Martínez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy. J Med Chem. 2018 Aug 9;61(15):6518-654.

  • Apaolaza I, San José-Eneriz E, Tobalina L, Miranda E, Garate L, Agirre X, Prósper F, Planes FJ. An in-silico approach to predict and exploit synthetic lethality in cancer metabolism. Nat Commun. 2017 Sep 6;8(1):459.

  • San José-Enériz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, Ugarte A, Roa S, Paiva B, Estella-Hermoso de Mendoza A, Alvarez RM, Casares N, Segura V, Martín-Subero JI, Ogi FX, Soule P, Santiveri CM, Campos-Olivas R, Castellano G, de Barrena MGF, Rodriguez-Madoz JR, García-Barchino MJ, Lasarte JJ, Avila MA, Martinez-Climent JA, Oyarzabal J, Prosper F. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017 May 26;8:15424.

  • Agirre, X; Castellano, G; Pascual, M; Heath, S; Kulis, M; Segura, V; Bergmann, A; Esteve, A; Merkel, A; Raineri, E; Agueda, L; Blanc, J; Richardson, D; Clarke, L; Datta, A; Russinol, N; Queiros, AC; Beekman, R; Rodriguez-Madoz, JR; San Jose-Eneriz, E; Fang, F; Gutierrez, NC; Garcia-Verdugo, JM; Robson, MI; Schirmer, EC; Guruceaga, E; Martens, JHA; Gut, M; Calasanz, MJ; Flicek, P; Siebert, R; Campo, E; Miguel, JFS; Melnick, A; Stunnenberg, HG; Gut, IG; Prosper, F; Martin-Subero, JI. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res. 2015;25(4):478-87.

  • Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, Odero MD. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia. 2014 Sep;28(9):1915-8.

  • Pérez C, Pascual M, Martín-Subero JI, Bellosillo B, Segura V, Delabesse E, Álvarez S, Larrayoz MJ, Rifón J, Cigudosa JC, Besses C, Calasanz MJ, Cross NC, Prósper F, Agirre X. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica. 2013;98:1414-1420.

  • Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, José-Eneriz ES, Mi- randa E, Martín-Subero JI, Garate L, Blanco-Prieto MJ, García de Jalón JA, Rio P, Rifón J, Cigudosa JC, Mar- tinez-Climent JA, Román-Gómez J, Calasanz MJ, Ribera JM, Prósper F. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia. 2012 Jul;26(7):1517-26.

  • Agirre X, Martínez-Climent JÁ, Odero MD, Prósper F. Epigenetic regulation of miRNA genes in acute leukemia. Leukemia. 2012;26:395-403.


"Nuestros estudios han dado lugar al desarrollo de una patente y una línea de trabajo en tipos de tumores humanos con mal pronóstico y sin una terapia eficaz", Dr. Prósper, investigador principal.

Contactar

Contacto:
Marisol Ripa
Avda. Pío XII, 55
31008 Pamplona
España

(+34) 948 194 700 Ext. 1010
msripa@unav.es